

Zydus invests in Feldan Therapeutics to drive innovation in intracellular drug delivery

17 April 2025 | News

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells



Zynext Ventures USA LLC, the venture capital arm of Ahmedabad-based Zydus Lifesciences, has announced its investment in Feldan Therapeutics, a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics.

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life.

Additionally, Feldan is advancing a pulmonary programme that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases.

Jay Kothari, Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio."